Oxaliplatin for injection
Function and Efficacy
This product is a new platinum derivative, the central platinum atom is surrounded by oxalic acid and 1.2-diaminocyclohexane, in a trans conformation, and is a stereoisomer. Like other platinum derivatives, oxaliplatin acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. Oxaliplatin binds to DNA rapidly, taking up to 15 minutes, while cisplatin binds to DNA in two phases, including a delayed phase after 48 hours. One hour after administration in the human body, its presence can be shown by measuring adducts in white blood cells. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin.
Ingredients
The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| OxaliplatinIngredients |
It is a new platinum derivative. The central platinum atom is surrounded by oxalic acid and 1,2-diaminocyclohexane, presenting a trans conformation, and is a stereoisomer. It acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA rapidly, taking up to 15 minutes. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin. More |
61825-94-3 | 56 |
Appearance
This product is white or off-white loose mass or amorphous solid or powder.
Indication
It can be used alone or in combination with fluorouracil for patients with colorectal cancer metastasis who have failed treatment with fluorouracil.
Usage and Dosage
When used alone or in combination, the recommended dose is 130 mg/m2, added to 250-500 ml of 5% glucose solution and infused for 2-6 hours. When no major toxicity occurs, the drug is administered once every 3 weeks (21 days). Dose adjustment should be based on safety, especially neurological safety.
Adverse Reactions
1. The main adverse reactions in hematology are: anemia, leukopenia, granulocytopenia and thrombocytopenia. 2. The main adverse reactions in non-hematology are: nausea, vomiting, diarrhea. 3. Nervous system: The main manifestation is peripheral neuritis, sometimes there may be spasms and sensory disorders around the mouth, upper respiratory tract and upper digestive tract.
Precautions
1. It is contraindicated for those who are allergic to platinum derivatives. 2. It should be used with caution during pregnancy and lactation.
Special Population Medication
Precautions for children: No such test has been conducted and no reliable references are available. Precautions for pregnancy and lactation: Possibly toxic to the fetus. This product is contraindicated during pregnancy. Studies on excretion through breast milk have not been conducted and it is contraindicated during lactation. Precautions for the elderly: No such test has been conducted and no reliable references are available.
Drug Interactions
This trial has not been conducted and there are no reliable references.
Storage
Sealed and stored below 25°C.
Packaging Specification
50 mg
Validity Period
24 months
Manufacturer
Nanjing Pharmaceutical FACTORY Co., Ltd.
-
Founded in:
1991-07-11 -
Address:
No. 26, Xingang Avenue, Nanjing Economic and Technological Development Zone -
Tax NO.:
91320192134908655F -
Registered Funds:
200.8 million yuan -
Website:
-
Email: